PROVECTUS BIOPHARMACEUTICALS PVCT
COM · Common Stock · CUSIP 74373P108
- SectorHealth care
- IndustryPharmaceutical Preparations
- HeadquartersKnoxville, TN
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Shares outstanding: 420.3m as of 2026-08-11, from the company's own SEC filing; the percentage can still exceed 100%: lent-out shares are counted by the lender and the buyer, and some reports overlap without saying so. Implied quarter-end price ≈ $0.07.
Trends to Q2 2026
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 7 |
| Q4 2022 | 7 |
| Q1 2023 | 7 |
| Q2 2023 | 7 |
| Q3 2023 | 6 |
| Q4 2023 | 7 |
| Q1 2024 | 6 |
| Q2 2024 | 7 |
| Q3 2024 | 7 |
| Q4 2024 | 6 |
| Q1 2025 | 7 |
| Q2 2025 | 7 |
| Q3 2025 | 7 |
| Q4 2025 | 5 |
| Q1 2026 | 6 |
| Q2 2026 | 4 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q3 2024 | 0 | 2 |
| Q4 2024 | 0 | 1 |
| Q1 2025 | 0 | 0 |
| Q2 2025 | 0 | 0 |
| Q3 2025 | 1 | 0 |
| Q4 2025 | 0 | 2 |
| Q1 2026 | 1 | 0 |
| Q2 2026 | 0 | 2 |
Biggest buyers
| None |
Biggest sellers
| Wealth Preservation Advisors, LLC | Sold out | -52.6k |
| ACADEMY CAPITAL MANAGEMENT | Sold out | -20.0k |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| Pershing Edward 13D · may seek influence +1.0 pts · filed 2026-07-22 | 11.6% |
Rodrigues Dominic
13D · may seek influence
new · filed 2025-12-08
Stated purposeThe Reporting Person acquired the securities for investment purposes. In his capacity as a director and executive officer of the Issuer, the Reporting Person may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Subject to the Issuer's Insider Trading Policy, the Reporting Person may from time to time buy or sell securities of the Issuer as appropriate for his personal circumstances. Except as described herein, the Reporting Person does not have any present plans or proposals that relate to or would result in any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Person may, from time to time, purchase addition… Full filing |
5.7% |
Insider purchases and sales since 1 Apr 2026
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
None reported since 1 Apr 2026.
Holders, Q2 2026
| Manager | Shares | Change |
|---|---|---|
| HOME FEDERAL BANK OF TENNESSEE 0.00% of their portfolio | 100.0k $6.9k | Unchanged |
| Atlas Wealth LLC 0.00% of their portfolio | 19.6k $1.4k | Unchanged |
| Financial Symmetry Inc 0.00% of their portfolio | 10.2k $707 | Unchanged |
| HUNTINGTON NATIONAL BANK 0.00% of their portfolio | 1 $0 | Unchanged |